Drug name - Dexilant

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(4 months from now)

CN1355798A TAKEDA PHARMS USA Benzimidazole Compound Crystal
Jun, 2020

(2 years ago)

CN1150186C TAKEDA PHARMS USA Benzimidazole Compound Crystal
Jun, 2020

(2 years ago)

EP1977751B1 TAKEDA PHARMS USA Amorphous (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole As Anti-Ulcer Agent
Jun, 2020

(2 years ago)

EP1977751A1 TAKEDA PHARMS USA Amorphous (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole As Anti-Ulcer Agent
Jun, 2020

(2 years ago)

EP1129088A2 TAKEDA PHARMS USA Crystalline Form Of (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole
Jun, 2020

(2 years ago)

EP1129088B1 TAKEDA PHARMS USA Crystalline Form Of (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole
Jun, 2020

(2 years ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal Jul, 2023

(10 months from now)

US8784885 TAKEDA PHARMS USA Controlled release preparation Oct, 2023

(1 year, 17 days from now)

US8722084 TAKEDA PHARMS USA Controlled release preparation Oct, 2023

(1 year, 17 days from now)

US8722084

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation Apr, 2024

(1 year, 6 months from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation Apr, 2024

(1 year, 6 months from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form Jan, 2026

(3 years from now)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form Jan, 2026

(3 years from now)

US9011926 TAKEDA PHARMS USA Method for producing granules Feb, 2026

(3 years from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form Jul, 2026

(3 years from now)

US7790755 TAKEDA PHARMS USA Controlled release preparation Aug, 2026

(3 years from now)

US8105626 TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount Sep, 2026

(4 years from now)

US7790755

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation Feb, 2027

(4 years from now)

US8105626

(Pediatric)

TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount Mar, 2027

(4 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules Jan, 2028

(5 years from now)

US8173158 TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food Mar, 2030

(7 years from now)

US8173158

(Pediatric)

TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food Sep, 2030

(7 years from now)

US9233103 TAKEDA PHARMS USA Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy Mar, 2032

(9 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: For the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (gerd); to maintain healing of ee and relief of heartburn; for healing of all grades of erosive esophagitis (ee); Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; healing of all grades of erosive esophagitis (ee) for up to 8 weeks; maintain healing of erosive esophagitis (ee) for up to 6 months; Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG CAPSULE, DELAYED RELEASE;ORAL Prescription
60MG CAPSULE, DELAYED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.